{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T12:13:09Z","timestamp":1775650389419,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04672-1","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:26:38Z","timestamp":1772519198000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of the efficacy of transarterial chemoembolization combined with radiofrequency ablation or sintilimab and bevacizumab for unresectable hepatocellular carcinoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Tingting","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengbin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"4672_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71 3","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71 3:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"Cancer J Clin"},{"key":"4672_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3350\/cmh.2024.0109","volume":"30 3","author":"H Crane","year":"2024","unstructured":"Crane H, Eslick GD, Gofton C, Shaikh A, Cholankeril G, Cheah M, et al. Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol. 2024;30 3:436\u201348. https:\/\/doi.org\/10.3350\/cmh.2024.0109.","journal-title":"Clin Mol Hepatol"},{"key":"4672_CR3","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1097\/00130404-200409000-00008","volume":"10 5","author":"ZC Zeng","year":"2004","unstructured":"Zeng ZC, Tang ZY, Fan J, Zhou J, Qin LX, Ye SL, et al. A comparison of chemoembolization combination with and without radiotherapy for unresectable hepatocellular carcinoma. Cancer J (Sudbury Mass). 2004;10 5:307\u201316. https:\/\/doi.org\/10.1097\/00130404-200409000-00008.","journal-title":"Cancer J (Sudbury Mass)"},{"key":"4672_CR4","doi-asserted-by":"publisher","first-page":"e3754","DOI":"10.1097\/md.0000000000003754","volume":"95 20","author":"C Tang","year":"2016","unstructured":"Tang C, Shen J, Feng W, Bao Y, Dong X, Dai Y, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma: A retrospective study. Medicine. 2016;95 20:e3754. https:\/\/doi.org\/10.1097\/md.0000000000003754.","journal-title":"Medicine"},{"key":"4672_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4103\/ijri.IJRI_352_18","volume":"29 1","author":"Y Patidar","year":"2019","unstructured":"Patidar Y, Garg L, Mukund A, Sarin SK. Early experience of combination therapy of transarterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma measuring 3\u20137\u00a0cm. Indian J Radiol Imaging. 2019;29 1:47\u201352. https:\/\/doi.org\/10.4103\/ijri.IJRI_352_18.","journal-title":"Indian J Radiol Imaging"},{"key":"4672_CR6","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.2147\/jhc.S424009","volume":"10","author":"J Yang","year":"2023","unstructured":"Yang J, Liang S, Liu H, Hu C, Guan S, Kang H, et al. Efficacy and safety of microwave ablation assisted by ultrasound fusion imaging for primary and secondary liver cancers with a diameter of 3\u20137 cm. J Hepatocellular Carcinoma. 2023;10:1839\u201348. https:\/\/doi.org\/10.2147\/jhc.S424009.","journal-title":"J Hepatocellular Carcinoma"},{"key":"4672_CR7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.2147\/jhc.S497956","volume":"11","author":"YT Chen","year":"2024","unstructured":"Chen YT, Chen BW, Xu JM, You XC, Tang Y, Wu SJ, et al. Multicenter study on transarterial chemoembolization combined with radiofrequency ablation for Early-Stage hepatocellular carcinoma: primary versus recurrent HCC. J Hepatocellular Carcinoma. 2024;11:2441\u201352. https:\/\/doi.org\/10.2147\/jhc.S497956.","journal-title":"J Hepatocellular Carcinoma"},{"issue":"2","key":"4672_CR8","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3760\/cma.j.cn112138-20240805-00492","volume":"64","author":"H Yang","year":"2025","unstructured":"Yang H, Huang JT, Hu D, Zhong BY, Shen J, Zhu XL. [Efficacy and safety of transarterial chemoembolization combined with sintilimab and bevacizumab biosimilar for unresectable hepatocellular carcinoma]. Zhonghua Nei Ke Za Zhi. 2025;64(2):134\u201341. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20240805-00492.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"4672_CR9","doi-asserted-by":"publisher","first-page":"153303382210751","DOI":"10.1177\/15330338221075174","volume":"21","author":"Y Teng","year":"2022","unstructured":"Teng Y, Ding X, Li W, Sun W, Chen J. A retrospective study on therapeutic efficacy of transarterial chemoembolization combined with immune checkpoint inhibitors plus lenvatinib in patients with unresectable hepatocellular carcinoma. Technol Cancer Res Treat. 2022;21:15330338221075174. https:\/\/doi.org\/10.1177\/15330338221075174.","journal-title":"Technol Cancer Res Treat"},{"key":"4672_CR10","doi-asserted-by":"publisher","first-page":"783480","DOI":"10.3389\/fonc.2021.783480","volume":"11","author":"F Cao","year":"2021","unstructured":"Cao F, Yang Y, Si T, Luo J, Zeng H, Zhang Z, et al. The efficacy of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: A multicenter retrospective study. Front Oncol. 2021;11:783480. https:\/\/doi.org\/10.3389\/fonc.2021.783480.","journal-title":"Front Oncol"},{"key":"4672_CR11","doi-asserted-by":"publisher","first-page":"979","DOI":"10.62713\/aic.3341","volume":"95 5","author":"S Li","year":"2024","unstructured":"Li S, Zhao F, Sun M, Wang H, Bai J, Zhou L. Comparison of the efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation versus monotherapy in patients with liver cancer. Ann Ital Chir. 2024;95 5:979\u201386. https:\/\/doi.org\/10.62713\/aic.3341.","journal-title":"Ann Ital Chir"},{"key":"4672_CR12","doi-asserted-by":"publisher","unstructured":"Zhang N, Du Y, Yu Y, Wu Q, Bai W, Zhang W, et al. Transarterial chemoembolization combined with Atezolizumab plus bevacizumab versus transarterial chemoembolization combined with lenvatinib plus sintilimab as first-line therapy for advanced hepatocellular carcinoma. J Clin Oncol. 2025; 43: e16223\u2013e16223. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.e16223.","DOI":"10.1200\/JCO.2025.43.16_suppl.e16223"},{"key":"4672_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s00270-022-03141-y","volume":"45 6","author":"T Ouyang","year":"2022","unstructured":"Ouyang T, Cao Y, Chen L, Zheng C. Comparison of the efficacy among transcatheter arterial chemoembolization (TACE)-Radiofrequency ablation plus Apatinib, TACE plus Apatinib, and TACE alone for hepatocellular carcinoma: A retrospective study. Cardiovasc Interv Radiol. 2022;45 6:780\u201390. https:\/\/doi.org\/10.1007\/s00270-022-03141-y.","journal-title":"Cardiovasc Interv Radiol"},{"key":"4672_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3350\/cmh.2018.0090","volume":"25 3","author":"TH Kim","year":"2019","unstructured":"Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25 3:245\u201363. https:\/\/doi.org\/10.3350\/cmh.2018.0090.","journal-title":"Clin Mol Hepatol"},{"key":"4672_CR15","doi-asserted-by":"publisher","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European journal of cancer (Oxford, England: 1990). 2009;45(2):228\u2009\u2013\u200947. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","DOI":"10.1016\/j.ejca.2008.10.026"},{"issue":"1","key":"4672_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the common terminology criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas dermo-sifiliograficas. 2021;112(1):90\u20132. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009.","journal-title":"Actas dermo-sifiliograficas"},{"issue":"1","key":"4672_CR17","doi-asserted-by":"publisher","first-page":"96267","DOI":"10.4251\/wjgo.v17.i1.96267","volume":"17","author":"FD Wu","year":"2025","unstructured":"Wu FD, Zhou HF, Yang W, Zhu D, Wu BF, Shi HB, et al Transarterial chemoembolization combined with lenvatinib and sintilimab vs lenvatinib alone in intermediate-advanced hepatocellular carcinoma. World J Gastrointest Oncol. 2025;17(1):96267. https:\/\/doi.org\/10.4251\/wjgo.v17.i1.96267.","journal-title":"World J Gastrointest Oncol"},{"issue":"1","key":"4672_CR18","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1186\/s12885-023-11389-x","volume":"23","author":"F Cao","year":"2023","unstructured":"Cao F, Shi C, Zhang G, Luo J, Zheng J, Hao W Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus Atezolizumab and bevacizumab: a bicentric retrospective study. BMC Cancer. 2023;23(1):873. https:\/\/doi.org\/10.1186\/s12885-023-11389-x.","journal-title":"BMC Cancer"},{"key":"4672_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41571-024-00865-3","volume":"21 3","author":"P Sidaway","year":"2024","unstructured":"Sidaway P. Adjuvant sintilimab effective in high-risk HCC. Nat Reviews Clin Oncol. 2024;21 3:168. https:\/\/doi.org\/10.1038\/s41571-024-00865-3.","journal-title":"Nat Reviews Clin Oncol"},{"key":"4672_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/cancers13020210","volume":"13","author":"M Haist","year":"2021","unstructured":"Haist M, Stege H, Grabbe S, Bros M. The functional crosstalk between Myeloid-Derived suppressor cells and regulatory T cells within the immunosuppressive tumor microenvironment. Cancers. 2021;13:2. https:\/\/doi.org\/10.3390\/cancers13020210.","journal-title":"Cancers"},{"key":"4672_CR21","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1701\/3197.31744","volume":"110 7","author":"M Verrico","year":"2019","unstructured":"Verrico M, Rossi L, Bianco V, Tomao S. [Bevacizumab e Altri farmaci. Attivit\u00e0 e Sicurezza Degli agenti anti-VEGF nel carcinoma ovarico]. Recenti Prog Med. 2019;110 7:330\u20137. https:\/\/doi.org\/10.1701\/3197.31744.","journal-title":"Recenti Prog Med"},{"issue":"4","key":"4672_CR22","doi-asserted-by":"publisher","first-page":"e25895","DOI":"10.1016\/j.heliyon.2024.e25895","volume":"10","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Song Z, Chen J, Tang Z, Wang B. Molecular basis, potential biomarkers, and future prospects of OSCC and PD-1\/PD-L1 related immunotherapy methods. Heliyon. 2024;10(4):e25895. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e25895.","journal-title":"Heliyon"},{"key":"4672_CR23","doi-asserted-by":"publisher","unstructured":"Brackenier C, Kinget L, Cappuyns S, Verslype C, Beuselinck B, Dekervel J. Unraveling the synergy between Atezolizumab and bevacizumab for the treatment of hepatocellular carcinoma. Cancers. 2023;15(2). https:\/\/doi.org\/10.3390\/cancers15020348.","DOI":"10.3390\/cancers15020348"},{"key":"4672_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00432-024-05949-2","volume":"150 9","author":"C Shen","year":"2024","unstructured":"Shen C, Jiang W, Chen R, Li L, Wu Y, Tan L, et al. Transarterial chemoembolization combined with sintilimab and lenvatinib for the treatment of unresectable hepatocellular carcinoma: a retrospective study. J Cancer Res Clin Oncol. 2024;150 9:427. https:\/\/doi.org\/10.1007\/s00432-024-05949-2.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4672_CR25","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00330-005-0029-9","volume":"16 3","author":"A Veltri","year":"2006","unstructured":"Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol. 2006;16 3:661\u20139. https:\/\/doi.org\/10.1007\/s00330-005-0029-9.","journal-title":"Eur Radiol"},{"key":"4672_CR26","doi-asserted-by":"publisher","first-page":"100399","DOI":"10.1016\/j.ejro.2022.100399","volume":"9","author":"TJ Vogl","year":"2022","unstructured":"Vogl TJ, Jaraysa Y, Martin SS, Gruber-Rouh T, Savage RH, Nour-Eldin NA, et al. A prospective randomized trial comparing microwave and radiofrequency ablation for the treatment of liver metastases using a dual ablation system the Mira study. Eur J Radiol Open. 2022;9:100399. https:\/\/doi.org\/10.1016\/j.ejro.2022.100399.","journal-title":"Eur J Radiol Open"},{"key":"4672_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/s1470-2045(21)00252-7","volume":"22 7","author":"Z Ren","year":"2021","unstructured":"Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus Sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study. Lancet Oncol. 2021;22 7:977\u201390. https:\/\/doi.org\/10.1016\/s1470-2045(21)00252-7.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4672_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1158\/1078-0432.Ccr-22-1366","volume":"29","author":"SA Patel","year":"2023","unstructured":"Patel SA, Nilsson MB, Le X, Cascone T, Jain RK, Heymach JV. Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy. Clin Cancer Research: Official J Am Association Cancer Res. 2023;29(1):30\u20139. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-1366.","journal-title":"Clin Cancer Research: Official J Am Association Cancer Res"},{"key":"4672_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3892\/ol.2024.14572","volume":"28 3","author":"K Kimura","year":"2024","unstructured":"Kimura K, Katata Y, Umeda Y, Tanaka T, Yano S, Yoshida K, et al. Ramucirumab in second\u2013line advanced colorectal cancer therapy: A study on therapeutic outcomes and hepatic sinusoidal platelet aggregation. Oncol Lett. 2024;28 3:439. https:\/\/doi.org\/10.3892\/ol.2024.14572.","journal-title":"Oncol Lett"},{"key":"4672_CR30","doi-asserted-by":"publisher","first-page":"1213608","DOI":"10.3389\/fphar.2023.1213608","volume":"14","author":"N Li","year":"2023","unstructured":"Li N, Feng Y, Chen X, Li Y, Zhang C, Yin Y. Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study. Front Pharmacol. 2023;14:1213608. https:\/\/doi.org\/10.3389\/fphar.2023.1213608.","journal-title":"Front Pharmacol"},{"key":"4672_CR31","doi-asserted-by":"publisher","unstructured":"Chen R, Lin Q, Zhu Y, Shen Y, Xu Q, Tang H, et al. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children. Orphanet J Rare Dis. 2023;18(1):297. https:\/\/doi.org\/10.1186\/s13023-023-02861-9.","DOI":"10.1186\/s13023-023-02861-9"},{"key":"4672_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41591-023-02786-7","volume":"30 3","author":"K Wang","year":"2024","unstructured":"Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, et al. Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nat Med. 2024;30 3:708\u201315. https:\/\/doi.org\/10.1038\/s41591-023-02786-7.","journal-title":"Nat Med"},{"issue":"2","key":"4672_CR33","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41416-021-01557-w","volume":"126","author":"JCF Quintanilha","year":"2022","unstructured":"Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, et al. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patients. Br J Cancer. 2022;126(2):265\u201374. https:\/\/doi.org\/10.1038\/s41416-021-01557-w.","journal-title":"Br J Cancer"},{"key":"4672_CR34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","volume":"41 1","author":"M Bhardwaj","year":"2022","unstructured":"Bhardwaj M, Chiu MN, Pilkhwal Sah S. Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance. Cutan Ocul Toxicol. 2022;41 1:73\u201390. https:\/\/doi.org\/10.1080\/15569527.2022.2034842.","journal-title":"Cutan Ocul Toxicol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04672-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04672-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T11:27:14Z","timestamp":1775647634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04672-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4672"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04672-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study follows the Helsinki Declaration and the relevant provisions of the International Ethical Guidelines. All research procedures have been approved by the Beijing Shijitan Hospital Affiliated to Capital Medical University Ethics Committee (Approval number: IIT2024-106-002). Informed consent was waived for this retrospective study due to the exclusive use of de-identified patient data, which posed no potential harm or impact on patient care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}